<DOC>
	<DOC>NCT01947894</DOC>
	<brief_summary>The purpose of this study is to assess the long term treatment outcomes of Growth Hormone treatment in patients who are prescribed and treated with Genotropin. Also, plan to determine the relationships between clinical status, dosage schedule and response to Genotropin treatment. This study will also contribute to our knowledge of adult Growth Hormone Deficiency, including transition period in Childhood Onset Growth Hormone Deficiency and its treatment.</brief_summary>
	<brief_title>A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients</brief_title>
	<detailed_description>Patients within inclusion criteria are asked to participate in the study.</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Adult patients of 18 years of age and above and fulfilling one of the three alternatives ac below; 1. Newly diagnosed with GHD according to the current medical standard. 2. Diagnosed with GHD before 2013 and previously treated with Genotropin and followed in KIMS®. 3. Transition patients diagnosed with COGHD before 2013. Prescribed Genotropin at the time of inclusion. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Patients who participate in any concurrent clinical interventional trial where a nonauthorized or authorized study medication is used, during their participation in Swedish KIMS® Xtended. Concurrent studies which do not include any study interventional items (whether medications or devices) are allowed.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>